276 related articles for article (PubMed ID: 19026697)
1. Uncoupling between Ig somatic hypermutation and oncogene mutation in mouse lymphoma.
Vincent C; Truffinet V; Fiancette R; Petit B; Cogné N; Cogné M; Denizot Y
Biochim Biophys Acta; 2009 Feb; 1793(2):418-26. PubMed ID: 19026697
[TBL] [Abstract][Full Text] [Related]
2. [Molecular genetic features of sporadic Burkitt's lymphoma in children].
Yang WP; Huang H; Gong LP; Wu Y; Xu HY; Zou Y; Lü BB; Zhong HS; Deng QQ; Xiao Q; Zeng ST; Zhu CD
Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):819-24. PubMed ID: 21215097
[TBL] [Abstract][Full Text] [Related]
3. Ongoing hypermutation in the Ig V(D)J gene segments and c-myc proto-oncogene of an AIDS lymphoma segregates with neoplastic B cells at different sites: implications for clonal evolution.
Ikematsu H; Cerutti A; Zan H; Knowles DM; Ikematsu W; Casali P
Hum Immunol; 2000 Dec; 61(12):1242-53. PubMed ID: 11163079
[TBL] [Abstract][Full Text] [Related]
4. The 3' IgH locus control region is sufficient to deregulate a c-myc transgene and promote mature B cell malignancies with a predominant Burkitt-like phenotype.
Truffinet V; Pinaud E; Cogné N; Petit B; Guglielmi L; Cogné M; Denizot Y
J Immunol; 2007 Nov; 179(9):6033-42. PubMed ID: 17947677
[TBL] [Abstract][Full Text] [Related]
5. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Bemark M; Neuberger MS
Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597
[TBL] [Abstract][Full Text] [Related]
6. A role for AID in chromosome translocations between c-myc and the IgH variable region.
Dorsett Y; Robbiani DF; Jankovic M; Reina-San-Martin B; Eisenreich TR; Nussenzweig MC
J Exp Med; 2007 Sep; 204(9):2225-32. PubMed ID: 17724134
[TBL] [Abstract][Full Text] [Related]
7. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
[TBL] [Abstract][Full Text] [Related]
8. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma.
Gaidano G; Pasqualucci L; Capello D; Berra E; Deambrogi C; Rossi D; Maria Larocca L; Gloghini A; Carbone A; Dalla-Favera R
Blood; 2003 Sep; 102(5):1833-41. PubMed ID: 12714522
[TBL] [Abstract][Full Text] [Related]
9. Ongoing somatic hypermutation of the rearranged VH but not of the V-lambda gene in EBV-transformed rheumatoid factor-producing lymphoblastoid cell line.
Chezar I; Lobel-Lavi L; Steinitz M; Laskov R
Mol Immunol; 2008 Nov; 46(1):80-90. PubMed ID: 18718665
[TBL] [Abstract][Full Text] [Related]
10. In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development.
Yan Y; Park SS; Janz S; Eckhardt LA
Genes Chromosomes Cancer; 2007 Oct; 46(10):950-9. PubMed ID: 17639584
[TBL] [Abstract][Full Text] [Related]
11. NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer.
Kanda K; Hu HM; Zhang L; Grandchamps J; Boxer LM
J Biol Chem; 2000 Oct; 275(41):32338-46. PubMed ID: 10931834
[TBL] [Abstract][Full Text] [Related]
12. Richter's and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation.
Reiniger L; Bödör C; Bognár A; Balogh Z; Csomor J; Szepesi A; Kopper L; Matolcsy A
Leukemia; 2006 Jun; 20(6):1089-95. PubMed ID: 16541139
[TBL] [Abstract][Full Text] [Related]
13. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
14. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
Wang J; Boxer LM
J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
[TBL] [Abstract][Full Text] [Related]
15. AID-targeting and hypermutation of non-immunoglobulin genes does not correlate with proximity to immunoglobulin genes in germinal center B cells.
Gramlich HS; Reisbig T; Schatz DG
PLoS One; 2012; 7(6):e39601. PubMed ID: 22768095
[TBL] [Abstract][Full Text] [Related]
16. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
Jain VK; Judde JG; Max EE; Magrath IT
J Immunol; 1993 Jun; 150(12):5418-28. PubMed ID: 8515068
[TBL] [Abstract][Full Text] [Related]
17. A myeloma translocation-like model associating CCND1 with the immunoglobulin heavy-chain locus 3' enhancers does not promote by itself B-cell malignancies.
Fiancette R; Amin R; Truffinet V; Vincent-Fabert C; Cogné N; Cogné M; Denizot Y
Leuk Res; 2010 Aug; 34(8):1043-51. PubMed ID: 20018375
[TBL] [Abstract][Full Text] [Related]
18. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
19. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
[TBL] [Abstract][Full Text] [Related]
20. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells.
Madisen L; Groudine M
Genes Dev; 1994 Sep; 8(18):2212-26. PubMed ID: 7958890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]